Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating

in Colombia

Short title: Substitutions in SARS-CoV-2 Spike and nucleocapsid proteins

Carlos Franco-Muñoz[a, c,*], Diego A. Álvarez-Díaz [a, b], Katherine Laiton-Donato[a],

Magdalena Wiesner [d], Patricia Escandón [d], José A. Usme-Ciro [a,e], Nicolás D.

Franco-Sierra[f], Astrid C. Flórez-Sánchez[g,] Sergio Gómez-Rangel [i], Luz D.

Rodríguez-Calderon [i], Juliana Barbosa-Ramirez [i], Erika Ospitia-Baez[i], Diana M.

Walteros[h], Martha L. Ospina-Martinez[j], Marcela Mercado-Reyes.[a, b, k]

a. Unidad de Secuenciación y Genómica. Dirección de Investigación en Salud

Pública, Instituto Nacional de Salud. Bogotá - 111321, Colombia

b. Grupo de Salud Materna y Perinatal. Dirección de Investigación en Salud

Pública, Instituto Nacional de Salud. Bogotá - 111321, Colombia

c. Grupo de Parasitología. Dirección de Investigación en Salud Pública, Instituto

Nacional de Salud. Bogotá - 111321, Colombia

d. Grupo de Microbiología, Dirección de Investigación en Salud Pública, Instituto

Nacional de Salud, Bogotá, Colombia

e. Centro de Investigación en Salud para el Trópico–CIST, Universidad

Cooperativa de Colombia, Santa Marta. Santa Martha - 470003, Colombia

f. Programa Ciencias de la Biodiversidad, Instituto de Investigación de Recursos

Biológicos Alexander von Humboldt, Bogotá - 111311, Colombia.

g. Dirección de Redes en Salud Pública, Instituto Nacional de Salud. Bogotá -

111321, Colombia

h. Dirección de Vigilancia en Salud Pública, Instituto Nacional de Salud. Bogotá -

111321, Colombia

i. Grupo de Virología, Dirección de Redes en Salud Pública, Instituto Nacional de

Salud. Bogotá - 111321, Colombia

j. Dirección General, Instituto Nacional de Salud. Bogotá - 111321, Colombia

k. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud. Bogotá

- 111321, Colombia

Symbol

33   *Corresponding author: Grupo de Parasitología. Dirección de Investigación en

34   Salud Pública, Instituto Nacional de Salud. Bogotá - 111321, Colombia. E-mail:

35   cefrancom@unal.edu.co

Abstract

Introduction: SARS-CoV-2 is a new member of the genus *Betacoronavirus*,

responsible for the COVID-19 pandemics. The virus crossed the species barrier

and established in the human population due to its ability to exploit the ACE

receptor for virus entry, which is present and abundant in several tissues, including

the lung and respiratory tract, gastrointestinal tract and hearth. Virus interaction

with the cellular receptor is mediated by the surface protein, known as Spike.

Another structural protein of major importance in the Nucleocapsid, directly

interacting with the viral RNA to form the ribonucleocapsid, considered a

multifunctional protein, and being the target of the most molecular diagnostics

assays. Objective: To describe the frequency of substitutions in spike and

nucleocapsid proteins of SARS-CoV-2 circulating in Colombia and evaluate the

frequency of these substitutions in SARS-CoV-2 sequences from other countries of

South America. Materials and methods: Samples of 43 patients were included for

viral RNA detection by real-time RT-PCR using the Charité-Berlin protocol for the amplification of the SARS-CoV-2 E and RdRp genes. Genome sequences were obtained through the Oxford Nanopore and Illumina MiSeq technologies, following the artic.network "nCoV-2019 sequencing protocol". Available genomes were consulted from GISAID, GenBank, and Genome sequence archive (GSA) and a total of 371 genomes sequences from South America were included. The genome sequences were aligned with the Muscle tool using the MEGA X software. Substitution matrices of the Colombian sequences respect to the reference genome (NC_045512) at the nucleotide and amino acid levels were generated for the spike and nucleocapsid gene.

Results: substitution D614G in the amino acid sequence of spike protein was found in 86.7% of the Colombian sequences; substitutions G181V and D936Y in 2.3%, respectively. Five substitutions were found in the nucleocapsid protein, with substitution R203K and G204R being the most frequent (13.95 %) in Colombia. The substitutions D614G in Spike and R203K-G204R in nucleocapsid have a frequency of 83% and 28% respectively in sequences from South America.

Conclusion: Non-synonymous substitutions were found in the spike and nucleocapsid proteins in Colombian genomes, the most frequent being D614G in Spike and R203K-G204R in nucleocapsid. These substitutions are frequent in the genomes reported for other South American countries. It is necessary to continue with genomic surveillance of the changes in Spike and Nucleocapsid proteins during the SARS-CoV-2 pandemic in Colombia and South America, even more considering that these proteins are the most commonly used antigen in serological tests.

Highlights

- The spike and nucleocapsid proteins of SARS-CoV-2 circulating in Colombia and South-American countries have similar patterns of non-synonymous substitutions

• Substitutions D614G in Spike and R203K-G204R in Nucleocapsid are the

most frequent in Colombia and South-American countries

Key words

SARS-CoV-2, spike, nucleocapsid, Colombia, Non-synonymous substitutions,

Outbreak lineages.

1. Introduction

The recently emerged SARS-CoV-2 responsible for the coronavirus disease 2019

(COVID-19) pandemic, has increased significantly in the number of cases and

deaths, so that daily, about 70,000 new cases are reported globally

(WHO, 2020a, 2020c). In Colombia, the first case of COVID-19 was announced by

the Nation's Ministry of Health on March 6, in a traveler from Italy, after which the

number of patients has exceeded 10,000 and over 500 deaths (INS, 2020). The

SARS-CoV-2 genome consist of a single, positive-stranded RNA (ssRNA[+]), with

29,903 nucleotides long. This virus has shown an extraordinary infectiousness and

transmission capacity in the human population (He et al., 2020), even exploring

other vertebrate species (Shi et al., 2020). The SARS-CoV-2 genome has nine

open reading frames (ORFs); the first one, subdivided in ORF1a and ORF1b by

ribosomal frameshifting, encodes the polyproteins pp1a and pp1ab which are

processed into non-structural proteins involved in subgenomic/genome length RNA

synthesis and virus replication. Structural proteins, Spike (S), Envelope (E),

Membrane (M), and Nucleocapsid (N) are encoded in subgenomic mRNA

transcripts within ORFs 2, 4, 5, and 9, respectively (SIB, 2020; Yount et al., 2005)

Spike protein, a type I membrane glycoprotein, is the most exposed viral protein

recognized by the cellular receptor angiotensin-2-converting enzyme (ACE2)

during the infection of the lower respiratory tract and considered the main inducer

of neutralizing antibodies. The N protein is associated with the RNA genome to

form the ribonucleocapsid and is abundantly expressed during infection. Both N

and S proteins are highly immunogenic and most commercial COVID-19 diagnostic

assays (molecular and immunologic) target these proteins (Alvarez-Diaz et al.,

2020; Lee, Lin, Renia, & Ng, 2020).

Furthermore, non-synonymous mutations in the S and N proteins have been

reported, their implications in the potential emergence of antigenically distinct

and/or more virulent strains remain to be studied, although it was reported that

mutations in the receptor-binding domain (RBD) at the S protein of SARS-CoV-

related viruses disrupt the antigenic structure and binding activity of RBD to ACE2

(Du et al., 2009) Similarly, how non-synonymous mutations could impact the

antibody response and the specificity and sensitivity of serological tests for COVID-

19 diagnosis is unknown. Thus, identifying variable sites at these proteins can

provide a valuable resource for choosing the target antigens for the development of

SARS-CoV-2 vaccines, therapeutics and diagnostic tests (Du et al., 2009;

Jacofsky, Jacofsky, & Jacofsky, 2020). The objective of this study is to describe the

frequency of substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2

circulating in Colombia and evaluate the frequency of these substitutions in SARS-

CoV-2 sequences from other countries of South America.

2. Materials and methods

2.1 Ethics

This work was developed according to the national law 9/1979, decrees 786/1990

and 2323/2006, which establishes that the Instituto Nacional de Salud (INS) from

Colombia is the reference lab and health authority of the national network of

laboratories and in cases of public health emergency or those in which scientific

research for public health purposes as required. The INS is authorized to use the

biological material for research purposes, without informed consent, which includes

the anonymous disclosure of results. This study was performed following the

ethical standards of the Declaration of Helsinki 1964 and its later amendments.

The information used for this study comes from secondary sources of data that

were previously anonymized and do protect patient data.

2.2 Patients and samples

Nasopharyngeal swab samples from patients with suspected SARS-CoV-2

infection were processed for RNA extraction using the automated MagNA Pure LC

nucleic acid extraction system (Roche Diagnostics GmbH, Mannheim, Germany)

and viral RNA detection was performed by real-time RT-PCR using the SuperScript

III Platinum One-Step Quantitative RT-qPCR kit (Thermo Fisher Scientific,

Waltham, MA, USA), following the Charité-Berlin protocol (Corman et al., 2020) for

the amplification of the SARS-CoV-2 E (betacoronavirus screening assay) and

RdRp (SARS-CoV-2 confirmatory assay) genes.

2.3 Complete genome sequencing of SARS-CoV-2 through NGS

NGS of SARS-CoV-2 from 43 patients was performed using the amplicon-based

Illumina and Nanopore sequencing approaches, ARTIC network protocol (Quick,

2020a). Following cDNA synthesis with SuperScript IV reverse transcriptase

(Thermo Fisher Scientific, Waltham, MA, USA) and random hexamers (Thermo

Fisher Scientific, Waltham, MA, USA), a set of 400-bp tiling amplicons across the

whole genome of SARS-CoV-2 were generated using the primer schemes nCoV-

2019/V3 (Quick, 2020a).

SARS-CoV-2 specific oligonucleotides were used for the generation of amplicons

by means of a high-fidelity DNA polymerase (Q5® High-Fidelity DNA Polymerase -

(New England Biolabs Inc., UK, EB), in order to avoid the introduction of artificial

substitutions.

2.4 Sequence Analysis

Databases as GISAID, NCBI, and GSA were consulted and a total of 371

sequences were included. The South American sequences were aligned with the

Muscle tool (Edgar, 2004) using the MEGA X software (Kumar, Stecher, & Tamura,

2016). Substitutions matrices of SARS-CoV-2 sequences deposited in GISAID

(Table 1), compared to the reference genome (NC_045512) at the nucleotide and

amino acid levels were generated for the Spike and Nucleocapsid genes and

proteins. The Colombian sequences were analyzed to determine the frequency of

amino acid changes in Spike and Nucleocapsid proteins. Based on Phylogenetic

Assignment of Named Global Outbreak LINeages (PANGOLIN)

https://github.com/hCoV- 2019/pangolin different lineages were defined in

Colombian genomes.

3. Results

3.1 Non-synonymous substitutions in the Spike and Nucleocapsid proteins
176

Three amino acid changes were observed in the spike protein of Colombian SARS-

CoV-2 sequences compared to the reference sequence (NC_045512.2). Spike

protein substitution D614G is present in 81% (35/43) of the sequences reported in

this study. The following substitutions were also found in lower frequency: G181V

2.3% (1/43) and D936Y 2.3% (1/43) (Table 1). In nucleocapsid protein, five amino

acid changes were found when Colombian genomes reported in this study were

compared to the reference sequence (NC_045512.2). The most frequent changes

were R203K and G204R in 13.95% (6/43) of the sequences. Amino acid changes

R191C, R209I and G238C were found in 4.65% (2/43), 4.65% (2/43) and 6.97%

(3/43) of the Colombian sequences, respectively (Table 1). Some nucleotide

substitutions were synonymous.

Nonsynonymous substitution D614G in the spike protein was the most frequent

observed in Colombian sequences included in this study. Genomic resource

databases such as NCBI, GISAID and GSA were consulted to determine if the

predominant substitutions in genomes reported in Colombia were present in other

countries in South America. A total of 86 genomes from Colombia, 29 from

Argentina, 92 from Brazil, 143 from Chile, 4 from Ecuador, 2 from Peru and 11

from Uruguay were reported as of May 19th, 2020. G614 of SARS-CoV-2 was

frequent in Argentina, Brazil, Chile, Colombia and Peru, with 80-100% of the

reported sequences (Figure 1A). However, in Ecuador and Uruguay, D614G was

observed in less percentages, possibly related to the low number of genomes

reported or to the introduction history of SARS-CoV-2 in these countries. Finally,

some reported genomes had indeterminate nucleotides at the site of the

substitution and could not be included in the analysis.

3.2 Spatiotemporal distribution of substitutions in Spike and Nucleocapsid

A temporal analysis of the distribution of D614G in the 131 Colombian reported

genomes, including the genomes reported in this study, was performed using the

available collection sample data in the associated metadata (Figure 1B). Since the

first case report date in Colombia and during March 2020, 14% of Colombian

sequences exhibited aspartate at position 614 in the spike protein (D614), while in

April 2020, the frequency reduced to 4%.

Nonsynonymous substitutions R203K and G204R (13.95%), which are the

hallmarks of the B.1.1 lineage, were the most frequent substitutions in

Nucleocapsid protein of Colombian sequences included in this study. Both

substitutions are frequent in Argentina and Brazil, present in the 55% of the

reported sequences (Fig. 1C). In Peru, Ecuador and Chile the frequency were

similar to reported for Colombia, while in Uruguay the substitution was not present.

Temporal analysis of the distribution of the R203/G204 and K203/R204 subtypes of

the Nucleocapsid for the 131 Colombian genomes shows that the frequency of the

K203/R204 subtype was 9% in March 2020, and became 19% in April 2020 (Fig.

1D), suggesting that the frequency of this substitution could increase over time and

reach values similar to those reported for Brazil and Chile.

Regarding the other nonsynonymous substitutions that were observed in less

frequency, the G181V substitution of the spike protein, was observed in one

Colombian sequence and in two sequences from Brazil, while the D936Y

substitution of spike protein was not observed in other genomes from South

America. The R191C substitution in the nucleocapsid protein was observed in two

Colombian sequences and in another Argentina sequence, R209I was observed in

nine sequences from Chile and finally, G238C was exclusive to three Colombian

sequences.

3.3 Nonsynonymous substitutions and circulating lineages in Colombia

In the analysis of the nonsynonymous substitutions in the Spike protein of

Colombian sequences, the G181V substitution was observed in a Colombian

sequence classified as lineage B.1. The D614G substitution was observed in

sequences classified as lineage B.1, in sublineages B.1.1, B.1.3, B.1.5, B.1.8, and

B.1.11 and lineage B.2. The D936Y substitution was observed in sequences

classified as of lineage B.1.5. As for Nucleocapsid protein, the R191C substitution

was observed in two Colombian sequences of lineage B.1.5. The R203K and

G204R substitutions were observed in sequences classified as lineage B.1. Finally

the R209I substitution in sequences classified as lineage B.2.5 and G238C

substitution in sequences classified as the lineage A.5.

4. Discussion

The first COVID-19 case in Colombia was confirmed on March 6, 2020, from a

person who entered the country from Italy on February 26, 2020. In June 1th, a total

de 30.493 cases have been reported with 969 deaths (INS, 2020). This study

evidenced the presence of the D614G substitution in spike protein in 89.6%

(112/125) of sequences since March 10, 2020, while strains circulating in previous

dates reveal the original substitutions reported in Wuhan (Bhattacharyya et al.,

2020), including the first Colombian strain sequenced from a symptomatic patient

sampled on March 11, 2020, linked to the second generation of a transmission

chain starting with an imported case from Spain.

D614G was detected in 86% of sequences from March, 2020 and in 96% of

sequences from April, 2020, being present in most of the geographical

departments of Colombia with genomic information available. D614G has been

found in 13 departments located from the Caribbean coast to the Amazon region in

only 3 months since the first case was reported in Colombia. While several studies

have emphasized the potential role of the D614G substitution in favoring the virus

transmissibility (Becerra-Flores & Cardozo, 2020; Bhattacharyya et al., 2020;

Brufsky, 2020), our data only suggest a founder effect determined by the multiple

introduction of G614-bearing B.1 sublineages.

In-silico analysis of D614G substitution in Spike suggests a more stable union with

the ligand ACE2 (Becerra-Flores & Cardozo, 2020; Brufsky, 2020; Nakashima,

2020). Preliminary results suggest that the presence of D614G statistically

correlate with the mean number of deaths occurred in several European countries

and Brazil (Becerra-Flores & Cardozo, 2020). Korber et al proposes an association

with infectivity, rapid dispersion and high viral load in infected patients (Korber et

al., 2020). Kim et al suggested that this substitution could affect the ability to

activate long-term immune response against SARS-CoV-2. Antigenicity analysis of

amino acids 613 to 621 from Spike protein related decreases in the epitope

recognition in B cells, in charge of stimulating adaptive immune response by

producing antibodies. Therefore, this reduced immunogenicity leads to recurrent

infections by this lineage and must be a point to consider in vaccine development

(Kim, Nguyen, Park, Park, & Chung, 2020).

On the other hand, the double substitutions R203K and G204R in the

Nucleocapsid protein was also identified in South American sequences, in 28% of

the isolates with mutations in three consecutives nucleotides. Gupta et al reported

this alteration in isolates from Belgium, Brazil, Peru, Mexico, Nigeria, Switzerland,

Vietnam and India (Gupta & Mandal). Ayub observed an association between the

presences of this substitution with case fatality (Ayub, 2020). While the most amino

acid changes evidenced in the Spike and Nucleocapsid proteins cannot be directly

related to a specific lineage, as has been reported in previous studies

(Bhattacharyya et al., 2020; Korber et al., 2020), the B.1.1 lineage is defined by the

three-nucleotide mutation leading to the two consecutives amino acid changes.

RNA viruses are known to possess very high substitution rates (Li, Li, Cui, & Wu,

2020; Tang et al., 2020), leading to high genetic variability and to the action of the

evolutionary mechanisms of natural selection and genetic drift. Despite some

evolutionary changes may be in fact adaptive, it is important to be careful with

conclusions in the absence of an experimental model to evaluate the impact of

every mutation in the virus phenotype and virus-host interaction.

Recombinant proteins or synthetic peptides from SARS-CoV-2 derived from the

reported genomic information is a well-explored alternative for the production of

antigens to be used in serological tests, considering that the production of total

viral antigen implies biosafety challenges and the need for a BSL3 laboratory.

Taking into account that Spike and Nucleocapsid are the major immunogenic

proteins of SARS and MERS coronavirus and the first choice for producing

recombinant antigens (Yan, Chang, & Wang, 2020), it is essential to continue with

the evolutionary monitoring of genes included in the original designs of serological

tests, because amino acid changes can affect the conformational structure and

physical-chemical properties of the proteins. Considering that reduced

immunogenicity in Spike protein is associated with the D614G amino acid change,

it could also be having impact in serosurveillance studies in countries where the

subtype G614 is prevalent, such as Spain, where a seroprevalence of 5% was

registered (MSCBS, 2020).

5. **Conclusion**

Amino acid changes were found in the Spike and Nucleocapsid proteins in

Colombian genomes of SARS-CoV-2, the most frequent being D614G in Spike and

R203K-G204R in Nucleocapsid. These substitutions are frequent in the genomes

reported for other South American countries. It is necessary to continue with

genomic surveillance of changes in spike and nucleocapsid proteins during the

SARS-CoV-2 pandemic in Colombia and South America, even more considering

that these proteins are the most commonly antigen/target used in serological and

molecular tests. Identification of nucleotide substitutions, amino acid changes and

their frequency in the circulating virus in the region is an important information for

decision-making of public health, such as if a vaccine candidate is appropriate for a

specific population. Monitoring genetic variability is important for the refinement of

SARS-CoV-2 serological and molecular tests.

6. Acknowledgements

The authors thank the National Laboratory Network for routine virologic

surveillance of SARS-CoV-2 in Colombia. The authors thank all the Colombian and

foreign researchers who deposited genomes in GISAID's EpiFlu (TM) Database

contributing to genomic diversity and phylogenetic relationship of SARS-CoV-2.

Conflict of interests

The authors declare no competing interest.

Funding

This study was funded by the National Institute of Health, Bogota, Colombia

References

Alvarez-Diaz, D. A., Franco-Munoz, C., Laiton-Donato, K., Usme-Ciro, J. A., Franco-
Sierra, N. D., Florez, A. C., . . . Mercado-Reyes, M. (2020). Molecular analysis of
several in-house rRT-PCR protocols for SARS-CoV-2 detection in the context of
genetic variability of the virus in Colombia. *medRxiv*, 2020.2005.2022.20107292.
doi:10.1101/2020.05.22.20107292
Ayub, M. I. (2020). Reporting Two SARS-CoV-2 Strains Based on A Unique
Trinucleotide-Bloc Mutation and Their Potential Pathogenic Difference. *Published*
online April, 19.
Becerra☐Flores, M., & Cardozo, T. (2020). SARS☐CoV☐2 viral spike G614 mutation
exhibits higher case fatality rate. *International Journal of Clinical Practice*.
Bhattacharyya, C., Das, C., Ghosh, A., Singh, A. K., Mukherjee, S., Majumder, P. P., . . .
Biswas, N. K. (2020). Global Spread of SARS-CoV-2 Subtype with Spike Protein
Mutation D614G is Shaped by Human Genomic Variations that Regulate
Expression of TMPRSS2 and MX1 Genes. *bioRxiv*.

Brufsky, A. (2020). Distinct Viral Clades of SARS☐CoV☐2: Implications for Modeling of
Viral Spread. *Journal of Medical Virology*.
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., . . . Drosten,
C. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European
communicable disease bulletin, 25(3), 2000045. doi:10.2807/1560-
7917.ES.2020.25.3.2000045
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009). The spike protein of
SARS-CoV—a target for vaccine and therapeutic development. *Nature Reviews*
Microbiology, 7(3), 226-236.
Edgar, R. C. (2004). MUSCLE: multiple sequence alignment with high accuracy and high
throughput. *Nucleic Acids Res, 32*(5), 1792-1797. doi:10.1093/nar/gkh340
Gupta, A. M., & Mandal, S. Loss of Epitopes from SARS-Cov-2 Proteins for Non-
synonymous Mutations: A Potential Global Threat.
He, X., Lau, E. H., Wu, P., Deng, X., Wang, J., Hao, X., . . . Tan, X. (2020). Temporal
dynamics in viral shedding and transmissibility of COVID-19. *Nature medicine,*
26(5), 672-675.
INS. (2020). Coronavirus (COVID - 2019) en Colombia. Retrieved from
https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx
Jacofsky, D., Jacofsky, E. M., & Jacofsky, M. (2020). Understanding Antibody Testing for
COVID-19. *The Journal of Arthroplasty*.
Kim, S.-J., Nguyen, V.-G., Park, Y.-H., Park, B.-K., & Chung, H.-C. (2020). A Novel
Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their
Antigenicity and Immunogenicity? *Vaccines, 8*(2), 220.
Korber, B., Fischer, W., Gnanakaran, S. G., Yoon, H., Theiler, J., Abfalterer, W., . . .
Parker, M. D. (2020). Spike mutation pipeline reveals the emergence of a more
transmissible form of SARS-CoV-2. *bioRxiv*.
Kumar, S., Stecher, G., & Tamura, K. (2016). MEGA7: molecular evolutionary genetics
analysis version 7.0 for bigger datasets. *Molecular biology and evolution, 33*(7),
1870-1874.
Lee, C. Y.-P., Lin, R. T., Renia, L., & Ng, L. F. (2020). Serological Approaches for
COVID-19: Epidemiologic Perspective on Surveillance and Control. *Frontiers in*
Immunology, 11, 879.
Li, J., Li, Z., Cui, X., & Wu, C. (2020). Bayesian phylodynamic inference on the temporal
evolution and global transmission of SARS-CoV-2. *J Infect*.
doi:10.1016/j.jinf.2020.04.016
MSCBS. (2020). *ESTUDIO ENE-COVID19: PRIMERA RONDA ESTUDIO NACIONAL*
DE SERO-EPIDEMIOLOGÍA DE LA INFECCIÓN POR SARS-COV-2 EN
ESPAÑA. Spain: Ministerio de Sanidad - España Retrieved from
https://www.mscbs.gob.es/ciudadanos/ene-covid/home.htm.
Nakashima, A. (2020). The global emergences of multiple SARS-CoV-2 sub-strains:
Digital annotations for human behaviors may assist automated retracing of
symptomatic features and origins.
Quick, J. (2020a). nCoV-2019 sequencing protocol. Retrieved from
https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., . . . Sun, Z. (2020).
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–
coronavirus 2. *Science, 368*(6494), 1016-1020.
SIB. (2020). Betacoronavirus.   Retrieved from
https://viralzone.expasy.org/764?outline=all_by_species
Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., . . . Lu, J. (2020). On the origin and
continuing evolution of SARS-CoV-2. *National Science Review*.
doi:10.1093/nsr/nwaa036
WHO. (2020a). WHO Director-General's opening remarks at the media briefing on
COVID-19 - 11 March 2020.   Retrieved from
https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-
the-media-briefing-on-covid-19---11-march-2020
WHO. (2020c). Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for
2019-nCoV in humans.   Retrieved from
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-
guidance/laboratory-guidance
Yan, Y., Chang, L., & Wang, L. (2020). Laboratory testing of SARS☐CoV, MERS☐CoV,
and SARS☐CoV☐2 (2019☐nCoV): Current status, challenges, and
countermeasures. *Reviews in Medical Virology*, e2106.
Yount, B., Roberts, R. S., Sims, A. C., Deming, D., Frieman, M. B., Sparks, J., . . . Baric,
R. S. (2005). Severe acute respiratory syndrome coronavirus group-specific open
reading frames encode nonessential functions for replication in cell cultures and
mice. *J Virol, 79*(23), 14909-14922. doi:10.1128/JVI.79.23.14909-14922.2005
420

Table 1. Nucleotide substitutions and amino acid changes in the Spike and Nucleocapsid proteins of 43 genomes of SARS-CoV-2 from Colombia reported in this study. Location of the substitutions was estimated base on the reference genomic sequence NC_045512.2. Left panel: nucleotides; right panel: amino acids. ?: Uncovered nucleotide and amino acids during complete genome sequencing.

GISAID Accession ID	Sequence ID	Nucleotides — S (Spike)					Nucleotides — N (Nucleocapsid)							Aminoacids — S (Spike)			Aminoacids — N (Nucleocapsid)				
		22104	23403	23443	23707	24368	28844	28881	28882	28883	28893	28989	29269	181	614	936	190	203	204	209	238
	NC_045512_SARS-COV-2_Wuhan-Hu-1	G	A	T	C	G	C	G	G	G	G	G	C	G	D	D	R	R	G	R	G
EPI_ISL_456146	hCoV-19/Colombia/Bello/82457/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456118	hCoV-19/Colombia/Medellin/80370/2020	.	G	.	.	.	?	.	.	.	.	.	.	.	G	.	?	.	.	.	.
EPI_ISL_456145	hCoV-19/Colombia/Barranquilla/79743/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456120	hCoV-19/Colombia/Bogota/79190/2020	.	G	.	.	.	.	.	.	.	.	.	T	.	G	.	.	.	.	.	.
EPI_ISL_456116	hCoV-19/Colombia/Bogota/84861/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456126	hCoV-19/Colombia/Norte_de_Santander/80656/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456155	hCoV-19/Colombia/Pereira/80245/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456130	hCoV-19/Colombia/Cucuta/79504/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456131	hCoV-19/Colombia/Bucaramanga/79752/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456132	hCoV-19/Colombia/Ibague/80202/2020	.	G	C	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456134	hCoV-19/Colombia/Cali/79773/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456135	hCoV-19/Colombia/Cali/79779/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456138	hCoV-19/Colombia/Cali/79943/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456150	hCoV-19/Colombia/Cali/79965/2020	.	G	.	.	T	.	.	.	.	.	.	.	.	G	Y	.	.	.	.	.
EPI_ISL_456141	hCoV-19/Colombia/Palmira/81271/2020	.	G	.	?	?	.	.	.	.	.	.	.	.	G	?	.	.	.	.	.
EPI_ISL_456136	hCoV-19/Colombia/Cali/79929/2020	.	G	.	.	.	T	.	.	.	.	.	.	.	G	.	C	.	.	.	.
EPI_ISL_456137	hCoV-19/Colombia/Cali/79930/2020	.	G	.	.	.	T	.	.	.	.	.	.	.	G	.	C	.	.	.	.
EPI_ISL_418262	hCoV-19/Colombia/Bogota/78390/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456149	hCoV-19/Colombia/Bucaramanga/80123/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456154	hCoV-19/Colombia/Tumaco/103303/2020	T	G	.	.	.	.	A	A	C	.	.	.	V	G	.	.	K	R	.	.
EPI_ISL_456156	hCoV-19/Colombia/Barrancabermeja/94514/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456139	hCoV-19/Colombia/Cali/81251/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456142	hCoV-19/Colombia/Cali/81279/2020	.	G	.	.	?	.	A	A	C	.	.	.	.	G	?	.	K	R	.	.
EPI_ISL_456144	hCoV-19/Colombia/Leticia/103039/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456121	hCoV-19/Colombia/Cartagena/79738/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456148	hCoV-19/Colombia/Cartagena/79890/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456124	hCoV-19/Colombia/Popayan/80705/2020	.	G	.	.	?	.	.	.	.	.	.	.	.	G	?	.	.	.	.	.
EPI_ISL_456153	hCoV-19/Colombia/Cienaga/101935/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456125	hCoV-19/Colombia/Santa_Marta/81035/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456147	hCoV-19/Colombia/Bogota/96183/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456122	hCoV-19/Colombia/Cartagena/80191/2020	.	G	.	.	.	.	.	.	.	.	?	.	.	G	.	.	.	.	.	?
EPI_ISL_456129	hCoV-19/Colombia/Pereira/82099/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456140	hCoV-19/Colombia/Cartago/81264/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456143	hCoV-19/Colombia/Cali/82307/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456151	hCoV-19/Colombia/Cali/82320/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456117	hCoV-19/Colombia/Medellin/79253/2020	.	.	.	.	.	.	.	.	.	.	T	.	.	.	.	.	.	.	.	C
EPI_ISL_417924	hCoV-19/Colombia/Antioquia/79256/2020	.	.	.	.	.	.	.	.	.	.	T	.	.	.	.	.	.	.	.	C
EPI_ISL_456119	hCoV-19/Colombia/Medellin/80825/2020	.	.	.	.	.	.	.	.	.	.	T	.	.	.	.	.	.	.	.	C
EPI_ISL_456123	hCoV-19/Colombia/Manizales/79489/2020	.	.	.	.	.	?	.	.	.	.	?	.	.	.	.	?	.	.	.	?
EPI_ISL_456133	hCoV-19/Colombia/Cali/79449/2020	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
EPI_ISL_456152	hCoV-19/Colombia/Cali/96176/2020	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
EPI_ISL_456128	hCoV-19/Colombia/Armenia/80663/2020	.	.	.	T	.	.	.	.	.	T	.	.	.	.	.	.	.	.	I	.
EPI_ISL_456127	hCoV-19/Colombia/Armenia/79911/2020	.	.	.	T	.	.	.	.	.	T	.	.	.	.	.	.	.	.	I	.

Figure 1. Spatiotemporal distribution of the most frequently substitutions in Spike and Nucleocapsid of SARS-CoV-2. A. Distribution of subtypes D614 and G614 of spike protein in SARS-CoV-2 genomes reported as of May 19th, 2020 in Colombia and other South American countries; in red, variant D614 and in green, variant G614. **B.** Distribution of subtypes D614 and G614 of spike protein in SARS-CoV-2 genomes reported between March and April, 2020 in Colombia, according with the sample collection date, variant D614 and in green, variant G614. **C.** Distribution of subtypes R203/G204 and K203/R204 of nucleocapsid protein in SARS-CoV-2 genomes reported as of May 19th, 2020 in Colombia and other South American countries, in red, variant R203/G204 and in blue, variant K203/R204. **D.** Distribution of subtypes R203/G204 and K203/R204 of nucleocapsid protein in SARS-CoV-2 genomes reported between March and April, 2020 in Colombia, according with the sample collection date in Colombia, in red, variant R203/G204 and in blue, variant K203/R204.

GISAID Accession ID	Sequence ID	S 23104	S 23403	S 23447	S 24738	S 23778	N 28884	N 28888	N 28889	N 28892	N 28893	N 28989	N 29259	Saa 18	Saa 614	Saa 94	Naa 174	Naa 203	Naa 204	Naa 234	Naa 298
	NC_045512_SARS-COV-2_Wuhan-Hu-1	G	A	T	C	G	C	G	G	G	G	G	C	D	D	D	R	R	G	R	G
EPI_ISL_456146	hCoV-19/Colombia/Bello/82457/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456118	hCoV-19/Colombia/Medellin/80370/2020	.	G	.	.	.	?	.	.	.	.	.	.	.	G	.	?	.	.	.	.
EPI_ISL_456145	hCoV-19/Colombia/Barranquilla/79743/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456120	hCoV-19/Colombia/Bogota/79190/2020	.	G	.	.	.	.	.	.	.	.	T	.	.	G	.	.	.	.	.	.
EPI_ISL_456116	hCoV-19/Colombia/Bogota/84861/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456126	hCoV-19/Colombia/Norte_de_Santander/80656/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456155	hCoV-19/Colombia/Pereira/80245/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456130	hCoV-19/Colombia/Cucuta/79504/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456131	hCoV-19/Colombia/Bucaramanga/79752/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456132	hCoV-19/Colombia/Ibague/80202/2020	.	G	C	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456134	hCoV-19/Colombia/Cali/79773/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456135	hCoV-19/Colombia/Cali/79779/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456138	hCoV-19/Colombia/Cali/79943/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456150	hCoV-19/Colombia/Cali/79965/2020	.	G	.	T	.	.	.	.	.	.	.	.	.	G	Y	.	.	.	.	.
EPI_ISL_456141	hCoV-19/Colombia/Palmira/81271/2020	.	G	?	?	.	.	.	.	.	.	.	.	.	G	?	.	.	.	.	.
EPI_ISL_456136	hCoV-19/Colombia/Cali/79929/2020	T	G	.	.	.	.	.	.	.	.	.	.	.	G	.	C	.	.	.	.
EPI_ISL_456137	hCoV-19/Colombia/Cali/79930/2020	T	G	.	.	.	.	.	.	.	.	.	.	.	G	.	C	.	.	.	.
EPI_ISL_418262	hCoV-19/Colombia/Bogota/78390/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456149	hCoV-19/Colombia/Bucaramanga/80123/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456154	hCoV-19/Colombia/Tumaco/103303/2020	T	G	.	.	.	.	A	A	C	.	.	.	V	G	.	.	K	R	.	.
EPI_ISL_456156	hCoV-19/Colombia/Barrancabermeja/94514/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456139	hCoV-19/Colombia/Cali/81251/2020	.	G	.	.	.	.	A	A	C	.	.	.	.	G	.	.	K	R	.	.
EPI_ISL_456142	hCoV-19/Colombia/Cali/81279/2020	.	G	.	?	.	.	A	A	C	.	.	.	.	G	?	.	K	R	.	.
EPI_ISL_456144	hCoV-19/Colombia/Leticia/103039/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456121	hCoV-19/Colombia/Cartagena/79738/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456148	hCoV-19/Colombia/Cartagena/79890/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456124	hCoV-19/Colombia/Popayan/80705/2020	.	G	.	?	.	.	.	.	.	.	.	.	.	G	?	.	.	.	.	.
EPI_ISL_456153	hCoV-19/Colombia/Cienaga/101935/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456125	hCoV-19/Colombia/Santa_Marta/81035/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456147	hCoV-19/Colombia/Bogota/96183/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456122	hCoV-19/Colombia/Cartagena/80191/2020	.	G	.	.	.	.	.	.	.	.	.	?	.	G	.	.	.	.	.	?
EPI_ISL_456129	hCoV-19/Colombia/Pereira/82099/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456140	hCoV-19/Colombia/Cartago/81264/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456143	hCoV-19/Colombia/Cali/82307/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456151	hCoV-19/Colombia/Cali/82320/2020	.	G	.	.	.	.	.	.	.	.	.	.	.	G	.	.	.	.	.	.
EPI_ISL_456117	hCoV-19/Colombia/Medellin/79253/2020	.	.	.	.	T	.	.	.	.	.	.	C	.	.	.	.	.	.	.	.
EPI_ISL_417924	hCoV-19/Colombia/Antioquia/79256/2020	.	.	.	.	T	.	.	.	.	.	.	C	.	.	.	.	.	.	.	.
EPI_ISL_456119	hCoV-19/Colombia/Medellin/80825/2020	.	.	.	.	T	.	.	.	.	.	.	C	.	.	.	.	.	.	.	.
EPI_ISL_456123	hCoV-19/Colombia/Manizales/79489/2020	.	.	.	.	?	?	.	.	.	.	.	?	.	.	.	?	.	.	.	?
EPI_ISL_456133	hCoV-19/Colombia/Cali/79449/2020	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
EPI_ISL_456152	hCoV-19/Colombia/Cali/96176/2020	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
EPI_ISL_456128	hCoV-19/Colombia/Armenia/80663/2020	.	.	T	.	.	.	T	.	.	.	.	.	.	.	.	.	.	.	.	I
EPI_ISL_456127	hCoV-19/Colombia/Armenia/79911/2020	.	.	T	.	.	.	T	.	.	.	.	.	.	.	.	.	.	.	.	I